Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
RESEARCH TRIANGLE PARK, N.C., June 10, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Business Officer Greg Mossinghoff will present a...
-
G1T28 produced robust, transient, G1 cell cycle arrest of bone marrow cells Compound was well tolerated with predictable pharmacokinetic / pharmacodynamic activity Data support...
-
RESEARCH TRIANGLE PARK, N.C., May 13, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in...
-
RESEARCH TRIANGLE PARK, N.C., April 15, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs...
-
RESEARCH TRIANGLE PARK, N.C., April 8, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in...
-
RESEARCH TRIANGLE PARK, N.C., March 16, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs...
-
Proceeds to accelerate clinical development of lead CDK4/6 inhibitor for antineoplastic and chemoprotection indications Fred Eshelman and Peter Kolchinsky join board of...
-
RESEARCH TRIANGLE PARK, N.C., Feb. 2, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in...
-
Lead drug candidate is a highly potent and selective CDK4/6 inhibitor Data expected by early 2015 Initiation of Phase 1b/2a trial in oncology patients expected in second quarter of...
-
Team Advancing G1's Lead CDK 4/6 Inhibitor Toward Phase I Clinical Trials in Third Quarter RESEARCH PARK TRIANGLE, N.C., June 17, 2014 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a privately...